Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.66 |
| ▸ | LDHA | P00338 | 1/20 | 0.66 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | STAT1 | P42224 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.55 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL694906 | 0.83 | NPC1 (0.62) | KDM4ELDHAEPHX2MAPTHPGD | |
| SCHEMBL16719495 | 0.81 | ALDH1A1 (0.60) | KDM4EMAPTHPGDRAB9AALDH1A1 | |
| SCHEMBL1519746 | 0.80 | KDM4E (1.00) | KDM4ELDHAEPHX2MAPTHPGD | |
| SCHEMBL11231437 | 0.80 | KDM4E (0.76) | KDM4ELDHAEPHX2MAPTHPGD | |
| SCHEMBL16720914 | 0.75 | GAA (0.51) | KDM4EMAPTHPGDRAB9AALDH1A1 | |
| SCHEMBL16719399 | 0.75 | GAA (0.51) | KDM4EHPGDRAB9AALDH1A1NPC1 | |
| SCHEMBL694356 | 0.75 | CYP19A1 (0.68) | KDM4ELDHAEPHX2MAPTHPGD | |
| SCHEMBL9033788 | 0.74 | NPC1 (0.53) | KDM4EMAPTHPGDRAB9AALDH1A1 | |
| SCHEMBL695765 | 0.74 | KDM4E (0.61) | KDM4EMAPTHPGDRAB9AALDH1A1 | |
| SCHEMBL3333868 | 0.73 | KDM4E (0.67) | KDM4ELDHAEPHX2MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2012-04-19 | — | — | US | claimed |
| EP-1663962-A4 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORP (US) | 2007-08-22 | — | — | EP | claimed |
| JP-2007503392-A | — | — | 2007-02-22 | — | — | JP | claimed |
| EP-1663962-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2006-06-07 | — | — | EP | claimed |
| US-20050054651-A1 | Compositions and methods for the treatment of disease associated with Trp-p8 expression | DENDREON CORPORATION (US) | 2005-03-10 | — | — | US | claimed |
| WO-2005020897-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2005-03-10 | — | — | WO | claimed |
| US-20150266810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | V-BAC HOLDING CORP. (CA) | 2015-09-24 | — | — | US | disclosed |
| US-20130190296-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| US-8389730-B2 | Compositions and methods for the treatment of disease associated with TRP-P8 expression | DENDREON CORPORATION (US) | 2013-03-05 | — | — | US | disclosed |
| US-8362264-B2 | Tryptophan antagonist; anticancer agents | DENDREON CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
| EP-1663962-A4 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1663962-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050054651-A1 | Compositions and methods for the treatment of disease associated with Trp-p8 expression | DENDREON CORPORATION (US) | 2005-03-10 | — | — | US | disclosed |
| WO-2005020897-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190296-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | KDM4E 3888/4885LDHA 4604/4885EPHX2 3913/4885 |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | KDM4E 4239/4885LDHA 4062/4885EPHX2 3488/4885 |
| US-20150266810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | KDM4E 3849/4885LDHA 4623/4885EPHX2 4021/4885 |
| US-20050054651-A1 | Compositions and methods for the treatment of disease associated with Trp-p8 expression | TRPC4, TRPC3, TRPC1 | KDM4E 4239/4885LDHA 4062/4885EPHX2 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.